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Abstract
Background: Hep27 monoclonal (Hep27 Mab) is an antibody against hepatocellular carcinoma.
Hep27 Mab itself can inhibit the growth of a hepatocellular carcinoma cell line (HCC-S102). We
attempted to produce a single-chain fragment (scFv), a small fragment containing an antigen-binding
site of Hep27 Mab, by using DNA-recombinant techniques.
Results: The sequences encoding the variable regions of heavy (VH) and light (VL) chains of a
murine Hep27 Mab were linked together by a linker peptide (Gly4Ser)3 and tagged with a hexa-
histidine at the C-terminal; the resultant DNA construct was expressed in E. coli as an insoluble
protein. The denatured scFv was refolded and purified by immobilized metal ion affinity
chromatography (12 mg/l with a molecular weight of 27 kDa). Hep27scFv exhibited a tumoricidal
activity against the HCC-S102 cell as its parental antibody (Hep27 Mab).
Conclusion: This scFv may be a potential candidate for a targeting agent in HCC immunodiagnosis
or immunotherapy.
Background
Hep27 Mab is a monoclonal antibody raised against a
hepatocellular carcinoma cell line (HCC-S102). In a pre-
vious study, Hep27 Mab was identified as an anti-oncode-
velopmental antigen type (ODA) since it interacted not
only with HCC but also with normal fetal and newborn
livers. No interaction was observed in normal adult livers.
In addition, it reacted with the synthetic carbohydrate an-
tigen of glycolipid containing a mucin core unit. Moreo-
ver, as determined by FACS, the binding activity of Hep27
Mab to HCC cells treated with PDMP (1-phenyl-2-de-
canoylamino-3-morpholino-1-propanol, an inhibitor of
glycolipid synthesis) was decreased; indicating that
epitope recognized by Hep27 Mab should be a glycolipid.
Hep27 Mab alone inhibits the growth of an HCC-S102
cell line (65% viability) without effector cells [1]. The
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mechanism of tumor suppression is not known exactly,
but it may concerns the regulation of tumor cell prolifera-
tion by binding Hep27 Mab to the growth factor receptor
on the cell. This Mab may be potentially useful for human
hepatocellular carcinoma diagnosis and therapy. Howev-
er, the use of murine monoclonal antibodies for human
tumor diagnosis and therapy is limited by the human
anti-mouse antibody (HAMA) response. These limitations
may be overcome by a genetically engineered single-chain
antibody fragment (scFv) lacking an Fc domain [2]. These
small scFvs consist of a variable heavy chain (VH) and a
variable light chain (VL) linked together by a flexible
polypeptide linker [3]. These scFv molecules retain the
original antigen-binding site and, therefore, represent val-
uable molecules for targeted delivery of drugs, toxins, or
radioisotopes to a tumor site. Furthermore, scFv can be
produced on a large scale in bacteria or yeast [4,5], and it
can be manipulated by genetic engineering to form anti-
tumor fusion proteins with additional effector functions
[6,7].
This article reports our work about construction, expres-
sion, purification of a single-chain antibody fragment
(scFv), and characterization its biological function against
a human hepatocellular carcinoma cell line.
Results
Construction and expression of scFv
By using an assembly PCR that is described in the meth-
ods section, the fragments of VH and VL were assembled
together, yielding a fusion fragment encoding VH-VL with
a histidine tag at the C-terminal end (Figure 1B). They
then were cloned into the expression vector, pET8C as an
NcoI – Bpu1102I fragment. After linker insertion, positive
clones consisting of VH-linker-VL were selected and used
to perform DNA sequencing. A deduced amino acid se-
quence of VH and VL connected by a linker peptide,
(GGGGS)3, is shown in Figure 2.
The over expression of scFv was induced by adding IPTG
to the final concentration of 1 mM. The total cells, includ-
ing both soluble and insoluble fractions, were analyzed
by SDS-PAGE and immunoblotting. As shown in Figure 3,
an scFv-His fusion protein of about 27 kDa was strongly
expressed. The results showed that most of the scFv was
expressed as insoluble inclusion bodies. The scFv could
not be detected in a soluble fraction or in a culture medi-
um. Without IPTG induction, no scFv was detected even
in a whole cell fraction.
Refolding and purification of scFv
The purified Hep27scFv was analyzed by SDS-PAGE (Fig-
ure 4A) and immunoblotting (Figure 4B). The scFv ap-
peared as a single homogenous 27-kDa band. For this
experiment, a purified scFv yielded 12 mg/l of E. coli cell
culture. We analyzed the molecular weight of purified
scFv by using a superdex 75 column and comparing the re-
sults to standard molecules. As seen in Figure 5, the isolat-
ed scFv consisted mainly of a monomeric structure
(approximately 27 kDa) and small amounts of aggregated
scFv.
Figure 1
A construction of scFv. (A): Schematic representation of
scFv gene construction using overlapping PCR. The variable
regions of heavy chain (VH) and light chain (VL) were ampli-
fied separately by the 1st PCR. The VH and VL segments were
assembled by the second overlap PCR to generate the scFv
fragment. (B): Agarose gel analysis of PCR product of scFv.
Lane M, DNA marker (100 bp ladder); lane 1, the scFv PCR
products; lane 2, negative control (without templates).
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Figure 2
Nucleotide and deduced amino acid sequences of the constructed Hep27scFv containing VH, linker peptide,
and VL. The CDR regions are indicated by bold characters. The linker peptide is marked in box. Underlining indicates the
restriction enzyme sites used for cloning the Hep27scFv gene.
VH NcoI
ACGTCCATGGTCCAGCTGCTCGAGTCAGGGGGGGGCTTGGTGCAGCCTGGAGGGTCCCGG
TSM VQLLESGGGLVQPGGSR
AAACTCTCCTGTGCAGCCTCTGGATTCACTTTCAGTAGCTTTGGAATGCACTGGGTTCGT
KLSCAASGFTFSSFGMHWVR
CAGGCTCCAGAGAAGGGGCTGGAGTGGGTCGCATACATCAGTAGTGGCAGTAGTTCCATC
QAPEKGLEWVAYISSGSSSI
TACTATGCAGACACAGTGAAGGGCCGATTCACCATCTCCAGAGACAATCCCAAGAACACC
YYADTVKGRFTISRDNPKNT
CTGTTCCTGCAAATGACCAGTCTAAGGTCTGAGGACACGGCCATGTATTACTGTGCAAGA
LFLQMTSLRSEDTAMYYCAR
Linker
TCGGGGTTACTTCCATTTGACTACTGGGGCCAAGGCACCTCTCTCACAGTCTCGAGCGGT
SGLLPFDYWGQGTSLTVSSG
VL
GGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCGGAACTAGTGATGACCCAG
GGGSGGGGSGGGGSELVMTQ
ACTCCAGCTTCTTTGGCTGTGTCTCTAGGGCAGAGAGCCACCATCTCCTGCAGAGCCAGT
TPASLAVSLGQRATISCRAS
GAAAGTGTTGAATATTATGGCACAAGTTTAATGCAGTGGTACCAACAGAAACCAGGACAG
ESVEYYGTSLMQWYQQKPGQ
CCACCCAAACTCCTCATCTATGTTGCATCCAACGTAGAATCTGGGGTCCCTGCCAGGTTT
PPKLLIYVASNVESGVPARF
AGTGGCAGTGGGTCTGGGACAGACTTCAGCCTCAACATCCATCCTGTGGAGGAGGATGAT
SGSGSGTDFSLNIHPVEEDD
ATTGCAATGTATTTCTGTCAGCAAAGTAGGAAGGTTCCGTGGACGTTCGGTGGAGGCACC
IAMYFCQQSRKVPWTFGGGT
Bpu1102I
AAGCTGGAAATCAAACATCATCATCATCATCATTAATGAGCTGAGC
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The effects of Hep27scFv on HCC-S102 cell proliferation
In our previous study [1], we found that the viability of
HCC-S102 cells was reduced to 85 %, 83 % and 65 % on
the first, second, and third day, respectively, after treat-
ment with 5 g/ml of Hep27 Mab. No significant change
could be found in negative control (HCC-S102 treated
with Hep16 Mab, an Ab secreted from hybridoma clone
without tumuricidal activity). To investigate whether a
single scFv can inhibit tumor cell growth, we treated HCC-
S102 with various concentrations of Hep27scFv. The rela-
tive numbers of viable cells were then determined; the re-
sults are shown in Figure 6. Dose-dependent cytotoxic
effects were observed. The HCC-S102 cell proliferation
rate was reduced to 68% when the cells were treated with
20 g/ml of Hep27scFv for 72 h, but it was not changed
in negative control (0 g/ml Hep27scFv). Moreover, anti-
KOD DNA polymerase scFv (G1scFv) at a concentration
of 0–20 g/ml also was used as a negative control. The re-
sults showed that cancer cell proliferation could not be re-
duced. This experiment indicated that a refolded and
purified Hep27scFv retained a tumoricidal activity against
HCC-S102 as its parental antibody, Hep27 Mab.
Discussion
It has been confirmed that Hep27 Mab recognized a tu-
mor antigen on HCC-S102. Hep27 Mab showed no reac-
tivity to normal liver and low binding activity to HCC-
S102 treated with PDMP, an inhibitor of glycolipid syn-
thesis. Furthermore, Hep27 Mab alone can inhibit tumor
cell growth [1].
However, murine antibodies, as foreign proteins, may
elicit immune reactions that reduce or eliminate their
therapeutic efficacy and/or evoke allergic or hypersensitiv-
ity reactions in patients. Therefore, we attempted to pro-
duce Hep27scFv that may be useful in the
immunodiagnosis and immunotherapy of HCC.
In this study, we constructed a single-chain antibody frag-
ment, Hep27scFv. It consisted of the variable domains of
the heavy (VH) and light (VL) chains. The two variable do-
mains are linked via a flexible peptide, (GGGGS)3, to im-
prove the stability of the Fv domains. A variety of linkers
with different lengths and sequences has been used [3,8–
10]. Previous studies indicated that the lengths and se-
Figure 3
Protein fractionation analysis of scFv. (A): 12% SDS-PAGE of the gel was stained with 0.25% Coomassie Brilliant Blue R-
250. (B): Western blot. A fusion protein was probed with mouse anti-His Ab, followed by goat anti-mouse alkaline phosphatase
conjugated Ab. Color was developed by using NBT/BCIP alkaline phosphatase substrate. Lane M, protein molecular weight
marker; lane 1, total cells sample (without IPTG induction); lane 2, total cells sample (under IPTG induction) ; lane 3, culture
supernatant; lane 4, insoluble fraction; lane 5, soluble fraction. The scFv (27 kD) is denoted by an arrow.
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quences of the linker peptide could significantly affect the
properties of scFvs [11–14]. A short linker (0–10 residues)
hinders dimerization [13]. The most widely used linker
designs have sequences consisting primarily of stretches of
glycine (G) and serine (S) residues. Hydrophilic proper-
ties of serine allow hydrogen bonding to the solvent, and
glycines provide the necessary flexibility [11]. To facilitate
protein purification, the six-histidine residues were fused
at the C-terminal of scFv. Most of the scFv proteins were
expressed as inclusion bodies that were solubilized in
buffer containing 6 M GuHCl and refolded by step-wise
dilution of GuHCl to yield 12 mg/l with a molecular
weight about 27 kDa. These results were consistent with
the theoretical calculations. However, the gel filtration
profiles of purified Hep27scFv consisted of a monomeric
form with a molecular size of 27 kDa and a small amount
of non-specific aggregation products that also have been
reported by other groups [15–18]. Recently, Kurokawa et
al. reported overexpression of eukaryotic proteins con-
taining multiple disulfide bonds by coexpression with
Dsb protein [19,20]. Based on this strategy, it is a chal-
lenge to express scFv with disulfide bonds in a soluble
form in E. coli, so that scFv may directly be purified, char-
acterized, and employed without a protein refolding step.
We are now trying to express an active soluble protein of
Hep27scFv by using the Dsb coexpression system.
The results of a cell proliferation assay showed that
Hep27scFv has the potential to inhibit HCC-S102 cell
growth: there was a 32% reduction of cell proliferation
rate at a concentration of 20 g/ml of refolded and puri-
fied Hep27scFv. No change was observed in negative con-
trol (0 g/ml Hep27scFv) and the G1scFv-treated cells,
indicating that other types of scFv could not induce HCC-
S102 cell growth inhibition. Only Hep27scFv showed an
effect on tumor cell growth. These results also imply that
in vitro refolding yields a correct conformation of scFv and
that an incorrect form of refolded scFv will lead to protein
aggregation without biological function.
Although the mechanism of cancer cell death mediated by
Mab or scFv has not been characterized yet, it may be in-
volved in the binding between Mab or scFv and the
growth factor receptor on tumor cells [21–23]. Although
we did not study how scFv works on the same cells with-
out tumor antigen such as normal liver tissue, our previ-
ous study showed Hep27 Mab reacted against HCC-S102,
fetal and newborn livers but not against normal adult liv-
ers. In addition, the reactivity of Hep27 Mab against HCC-
S102 treated with PDMP, an inhibitor of glycolipid syn-
thesis, was decreased compared to untreated cells [1].
Therefore, we assumed that Hep27scFv consisting of a nu-
cleotide sequence encoding for the variable region of its
parental antibody (Hep27 Mab) would not recognize nor-
mal liver.
Conclusions
In view of our results, an active Hep27scFv could be pro-
duced in E. coli with high yield. Primary characterization
of the biological activity indicated that Hep27scFv
showed a potential tumoricidal activity against the hepa-
tocellular carcinoma cell line (HCC-S102) as its parental
antibody (Hep27 Mab). Therefore, it likely that
Hep27scFv has the potential to be a useful agent for im-
munodiagnostic and immunotherapeutic applications
against hepatocelllular carcinoma.
Methods
Construction of expression vector
To generate the scFv, the variable regions of heavy chain
and light chain encoding for Hep27 Mab obtained from
our previous study [1] were amplified separately using
specific primers. Heavy chain and light chain variable
fragments were fused together by using complementary
primer for the second PCR. To facilitate the purification
step, the 3' end primer of light chain was designed for his-
tidine residues. A negative control experiment was per-
formed without templates. Fusion fragments were then
ligated into pET8C. The complementary primer region of
Figure 4
SDS-PAGE and immunoblotting analysis of putified
scFv. ( A ) ;  S D S - P A G E  s t a i n e d  w i t h  C B B .  L a n e  M ,  p r o t e i n
molecular weight marker; lane 1, soluble proteins after
refolding; lane 2, Flow-through fraction; lane 3, washed frac-
tion; lane 4, eluted fraction. (B): Immunoblotting of purified
Hep27scFv stained with mouse anti-His antibody (IgG) and
alkaline phosphatase-conjugated anti-mouse IgG. Relative
molecular mass (kDa) of standard proteins is shown on the
left.
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VH-VL fusion fragments was then replaced by a linker pep-
tide consisting of three units of Gly4Ser [3] to obtain a sin-
gle chain fragment, VH-linker-VL, Hep27scFv (Figure 1).
Expression and protein purification
The vector pET8C-Hep27scFv, after being confirmed by
DNA sequencing, was transformed into BL21 (DE3). At a
mid-log growth phase, the Hep27scFv expression was in-
duced by the addition of isopropyl--D-thiogalactopyran-
oside (IPTG) to a final concentration of 1 mM, and cells
were further cultivated for 4 hr. The cells were harvested
by centrifugation at 12,000 g and resuspended in 1/2 vol-
ume of 30 mM Tris-HCl (pH8.0), 30 mM NaCl. Following
the disruption of the cell through sonication, the pellets
were dissolved in 1/20 volume of 2% Triton X-100. Then
the solution was sonicated and incubated at 4C for 16 hr.
The soluble proteins were solubilized in a Triton X-100
solution, and the pellets (inclusion bodies) were obtained
after centrifugation at 14,000 g for 15 min. The insoluble
protein was re-natured according to the methods of
Tsumoto et al. [24]. Briefly, the pellets were washed twice
with a 30 mM Tris-HCl (pH8.0), 30 mM NaCl buffer.
They were then solubilized in 50 mM Tris-HCl pH 8.0
containing 6 M Guanidine hydrochoride (GuHCl), 200
mM NaCl, 1 mM EDTA, 10 mM 2-mercaptoethanol (final
concentration of scFv = 7.5 M) and incubated overnight
at 4C. After removal of the mercaptoethanol by dialysis
against the same buffer without mercaptoethanol, GuHCl
was removed by dialysis against 100 mM Tris-HCl pH8.0
containing 3 M GuHCl and 200 mM NaCl, followed by
dialysis against the same buffer with step-wise reduction
in the GuHCl concentration (2,1,0.5, and 0 M). Each dial-
ysis was performed overnight. On a 1-M stage, 50-fold
molar excess of glutathione (GSSG) and 400 mM L-Ar-
ginine were added to the dialysis buffer. After dialysis, the
insoluble fraction containing insoluble E. coli proteins
and misfolded aggregates scFv was removed by centrifuga-
tion at 24,000 g for 30 min and then filtrated before the
purification step.
For protein purification, soluble proteins were dialyzed
against buffer A (0.02 M sodium phosphate buffer, 0.5 M
NaCl pH 7.2) and centrifuged before loading into a Cu2+
chelating column (1 ml) that was equilibrated with buffer
Figure 5
Gel filtration profiles. Gel filtration of purified and refolded Hep27scFv was performed on Superdex 75 column connected
to a FPLC system pre-equilibrated with PBS. Sample volume and flow rate were 200 l and 0.5 ml/min, respectively. Molecular
mass was calibrated with ovalbumin (44 kDa), myoglobulin (17 kDa), and vitamin B12 (1.35 kDa).
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A. The column was then washed with buffer A containing
25 mM imidazole, and proteins were then eluted with
buffer B (0.02 M sodium phosphate buffer, 0.5 M NaCl,
0.5 M imidazole, pH 7.2).
Gel filtration
To determine the molecular weight of refolded and puri-
fied scFv, we performed gel filtration using a Superdex 75
column (Amersham Pharmacia) connected to an FPLC
system and pre-equilibrated with PBS. Molecular mass
was calibrated with standard proteins of gel filtration
(Biorad). 200 l of refolded and purified Hep27scFv ad-
justed to 1 mg/ml was subjected to gel filtration at a flow
rate of 0.5 ml/min.
Cell proliferation assay
To evaluate the tumoricidal activity of Hep27scFv, we
used CellTiter 96AQueous Non-Radioactive cell prolifera-
tion Assay (Promega). This colorimetric assay employs
MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(-4-sulfophenyl)-2H-tetra-zolium, inner salt]
and electron coupling reagent, phenazine methosulfate
(PMS). The MTS assay depends on the activity of mitocon-
drial dehydrogenase to reduce MTS, and only mitochon-
dria in living cells have that activity. The amount of
formazan (reduced product of MTS) produced is propor-
tional to the number of living cells. HCC-S102 cells were
dispensed in a 96-well flat bottom titer plate at a concen-
tration of 5  103 cell in 100 l of Dulbecco's modified es-
sential medium (DMEM, life technologies) containing
10% of fetal bovine serum per well. After 4 hr of culture to
allow adhesion to the bottom of the wells, the HCC-S102
cells were treated with 0–20 g/ml of Hep27scFv for 72
hr. Cell proliferation rate was measured after 72 hr incu-
bation by adding 20 l of a fresh mixture of MTS/PMS so-
lution. The absorbance at 490 nm was measured in a
microplate reader as a measure of the relative amount of
viable cells in comparison with cells grown in the absence
of recombinant proteins. We calculated percent cell prolif-
eration of HCC-S102 by using the following formula:
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Figure 6
The effect of Hep27scFv on HCC-S102 cell growth in vitro. HCC-S102 cells were incubated with various concentra-
tions of Hep27scFv for 72 h. Cell proliferation rate was assayed by the MTS method and calculated as described in the methods
section. Cell proliferation rate reduced after treatment with various concentrations of scFv in a dose-dependent manner. The
rate reduced to 68% with 20 g/ml of Hep27scFv incubation but did not change either in negative control (0 g/ml scFv) or in
cells treated with G1scFv.
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